OM
ATXI

Opaleye Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Opaleye Management’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-875
Closed -$10.7M – 67
2020
Q3 		$10.7M Sell
875
-45
-5% -$547K 2.09% 17
2020
Q2 		$11.1M Hold
920
– – 2.25% 15
2020
Q1 		$9.25M Hold
920
– – 2.45% 14
2019
Q4 		$9.94M Buy
920
+73
+9% +$510K 1.95% 22
2019
Q3 		$5.68M Buy
847
+20
+2% +$136K 2.05% 24
2019
Q2 		$5.86M Buy
827
+116
+16% +$672K 1.79% 25
2019
Q1 		$3.8M Buy
711
+270
+61% +$1.72M 1.05% 36
2018
Q4 		$2.68M Buy
+441
New +$2.11M 1% 31

Other funds holding ATXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opaleye Management's ATXI Position: Q4 2020 in Review

Opaleye Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2020, closing a stake of 875 shares — an estimated $10.7M sold.

Opaleye Management first reported a position in ATXI in Q4 2018 and held it in 8 quarters. The position peaked at $11.1M in Q2 2020. 33 funds tracked by Wall St. Rank hold ATXI as of Q4 2020.

  • Opaleye Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Opaleye Management sold 875 Avenue Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $10.7M.
  • Opaleye Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2018 and held it in 8 quarters.
  • Opaleye Management's Avenue Therapeutics, Inc. Common Stock position peaked at $11.1M in Q2 2020.
  • 33 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Opaleye Management's 13F filing for Q4 2020, filed 12 Feb 2021.